(12) United States Patent (10) Patent No.: US 7,910,098 B2 Fuh Et Al
Total Page:16
File Type:pdf, Size:1020Kb
USOO79100.98B2 (12) United States Patent (10) Patent No.: US 7,910,098 B2 Fuh et al. (45) Date of Patent: Mar. 22, 2011 (54) ANT-VEGF ANTIBODES FOREIGN PATENT DOCUMENTS CA 2 O19559 12/1990 (75) Inventors: Germaine Fuh, Pacifica, CA (US); EP O 368 684 9, 2004 Chingwei V. Lee, Foster City, CA (US) WO WO93, 1116.1 6, 1993 WO WO95/27062 10, 1995 WO WO97/.44453 11, 1997 (73) Assignee: Genentech, Inc., South San Francisco, WO WO 97/45450 12/1997 CA (US) WO WO 98.45331 10, 1998 WO WOOO,34337 6, 2000 WO WO 2005/O12359 2, 2005 (*) Notice: Subject to any disclaimer, the term of this WO WO 2005/044853 5, 2005 patent is extended or adjusted under 35 WO WO 2005/123104 12/2005 U.S.C. 154(b) by 32 days. OTHER PUBLICATIONS (21) Appl. No.: 12/315,220 Rudikoffetal, Proc Natl Acad Sci USA 79: 1979-1983, 1982.* Barrios et al. J Molecular Recognition 17: 332-338, 2004.* (22) Filed: Dec. 1, 2008 MacCallum et al., J Mol. Biol 262: 732-745, 1996.* Wu et al., J. Mol. Biol. 294: 151-162, 1999.* Pini et al., “Design and Use of a Phage Display Library: Human (65) Prior Publication Data Antibodies with Subnanomolar Affinity Against a Marker of US 2009/O142343 A1 Jun. 4, 2009 Angiogenesis Eluted From a Two-Dimensional Gel.” J. Biol. Chem. 273:21769-21776 (1998). Adamis et al., “Inhibition of Vascular Endothelial Growth Factor Related U.S. Application Data Prevents Retinal Ischemia-Associated Iris Neovascularization in a Nonhuman Primate.” Arch. Ophthalmol. 114: 66-71 (1996). (60) Provisional application No. 60/991,302, filed on Nov. Aiello et al., “Vascular Endothelial Growth Factor in Ocular Fluid of 30, 2007. Patients with Diabetic Retinopathy and Other Retinal Disorders.” N. Engl. J. Med. 331: 1480-1487 (1994). Int. C. Barbas et al., “In vitro Evolution of a Neutralizing Human Antibody (51) to Human Immunodeficiency Virus Type 1 to Enhance Affinity and A 6LX39/395 (2006.01) Broaden Strain Cross-Reactivity.” Proc. Natl. Acad. Sci. USA 91: GOIN33/53 (2006.01) 3809-3813 (1994). CI2P 2L/08 (2006.01) Barbas et al., “Selection and Evolution of High-Affinity Human C07K 6/22 (2006.01) Anti-Viral Antibodies.” Tibtech. 14: 230-234 (1996). Barrios et al., “Length of the Antibody Heavy Chain Complementar (52) U.S. Cl. ............... 424/130.1; 424/133.1; 424/134.1; ity Determining Region 3 as a Specificity-Determining Factor.” J. 424/141.1; 424/142.1; 424/145.1; 435/7.1; Mol. Recongnit. 17: 332-338 (2004). 530/387.1:530/387.3; 530/388.1:530/388.15; Bass et al., “Hormone Phage: An Enrichment Method for Variant 530/388.24; 530/391.3 Proteins with Altered Binding Properties.” Proteins 8: 309-314 (58) Field of Classification Search ........................ None (1990). See application file for complete search history. Beiboer et al., “Guided Selection of a Pan Carcinoma Specific Anti body Reveals Similar Binding Characteristics Yet Structural Diver gence Between the Original Murine Antibody and Its Human Equiva (56) References Cited lent.” J. Mol. Biol. 296: 833-849 (2000). Berkman et al., “Expression of the Vascular Permeability Factor/ U.S. PATENT DOCUMENTS Vascular Endothelial Growth Factor Gene in Central Nervous System Neoplasms,” J. Clin. Invest. 91: 153-159 (1993). 4,774,378 9, 1988 Faure et al. Borgström et al., “Complete Inhibition of Angiogenisis and Growth 4,816,567 3, 1989 Cabilly et al. of Microtumors by Anti-Vascular Endothelial Growth Factor Neu 5,427,908 6, 1995 Dower et al. tralizing Antibody: Novel Concepts of Angiostatic Therapy from 5.432.018 7, 1995 Dower et al. 5,498,530 3, 1996 Schatz et al. Intravital Videomicroscopy.” Cancer Res. 56: 4032-4039 (1996). 5,580,717 12, 1996 Dower et al. Brekken et al., “Vascular Endothelial Growth Factor as a Marker of 5,658,727 8, 1997 Barbas et al. Tumor Endothelium.” Cancer Res. 58: 1952-1959 (1998). 5,688,666 11, 1997 Bass et al. Brown et al., “Expression of Vascular Permeability Factor (Vascular 5,723,286 3, 1998 Dower et al. Endothelial Growth Factor) and Its Receptors in Adenocarcinomas of 5,733,743 3, 1998 Johnson et al. the Gastrointestinal Tract.” Cancer Res. 53: 4727-4735 (1993). 5,750,373 5, 1998 Garrard et al. Brown et al., “Expression of Vascular Permeability Factor (Vascular 5,821,337 10, 1998 Carter et al. Endothelial Growth Factor) and Its Receptors in Breast Cancer.” 5,837,242 11, 1998 Holliger et al. Hum. Pathol. 26: 86-91 (1995). 5,928,641 7, 1999 Seon et al. 5,969, 108 10, 1999 McCafferty et al. (Continued) 6,054,297 4, 2000 Carter et al. 6,172,197 1, 2001 McCafferty et al. Primary Examiner — Phuong Huynh 6,342,219 1, 2002 Thorpe et al. (74) Attorney, Agent, or Firm — Clark & Elbing LLP 6,416,758 T/2002 Thorpe et al. 6,703,020 3, 2004 Thorpe et al. (57) ABSTRACT 6,884,879 4, 2005 Baca et al. 7,208,582 4, 2007 Rosen et al. The invention herein provides isolated antibodies that bind to 7,691977 4, 2010 Fuh et al. ................... 530,387.1 VEGF. The invention further provides methods of making 2005, 0186208 8, 2005 Fyfe et al. 2006/0280747 12, 2006 Fuh et al. ................... 424,155.1 anti-VEGF antibodies, and polynucleotides encoding anti 2007/002O267 1/2007 Fuh et al. ................... 424,145.1 VEGF antibodies. 2007/O141065 6, 2007 Fuh et al. ................... 424,155.1 2008/024.8033 10, 2008 Ferrara et al. 19 Claims, 11 Drawing Sheets US 7,910,098 B2 Page 2 OTHER PUBLICATIONS Guerrin et al., “Vasculotropin/Vascular Endothelial Growth Factor Is an Autocrine Growth Factor for Human Retinal Pigment Epithelial Carmelietet al., "Abnormal Blood Vessel Development and Lethality Cells Cultured in Vitro.” J. Cell. Physiol. 164: 385-394 (1995). in Embryos Lacking a Single VEGF Allele.” Nature 380: 435-439 "Guidelines for the Management of Rheumatoid Arthritis: 2002 (1996). Update.” Arthritis Rheum. 46: 328-346 (2002). Carmeliet et al., “Angiogenesis in Cancer and Other Diseases.” Hawkins et al., “Selection of Phage Antibodies by Binding Affinity. Nature 407:249-257 (2000). Mimicking Affinity Maturation.” J. Mol. Biol. 226: 889-896 (1992). Carter et al., “High Level of Escherichia coli Expression and Pro Hecht et al., “A Randomized Phase IIIB Trial of Chemotherapy, duction of a Bivalent Humanized Antibody Fragment.” Biotechnol Bevacizumab, and Panitumumab Compared With Chemotherapy and ogy 10: 163-167 (1992). Bevacizumab Alone for Metastatic Colorectal Cancer. J. Clin. Carter et al., “Humanization of an Anti-p185HER2 Antibody for Oncol. 27: 672-680 (2009). Human Cancer Therapy.” Proc. Natl. Acad. Sci. USA 89: 4285-4289 Holliger et al., “Diabodies: Small Bivalent and Bispecific Antibody (1992). Fragments.” Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993). Chen et al., “Selection and Analysis of an Optimized Anti-VEGF Hoogenboom et al., “Antibody Phage Display Technology and Its Antibody: Crystal Structure of an Affinity-Matured Fab in Complex Applications.” Immunotechnology 4:1-20 (1998). with Antigen.” J. Mol. Biol. 293:865-881 (1999). Houcket al., “The Vascular Endothelial Growth Factor Family: Iden Chothia et al., “Canonical Structures for the Hypervariable Regions tification of a Fourth Molecular Species and Characterization of of Immunoglobulins,” J. Mol. Biol. 196:901-917 (1987). Alternative Splicing of RNA.” Mol. Endocrinol. 5: 1806-1814 Christinger et al., “Crystallization of the Receptor Binding Domain (1991). of Vascular Endothelial Growth Factor.” Proteins 26: 353-357 Jackson et al., “In Vitro Antibody Maturation: Improvementofa High (1996). Affinity, Neutralizing Antibody Against IL-1 Beta.” J. Immunol. 154: Clackson et al., “Making Antibody Fragments Using Phage Display 3310-3319 (1995). Libraries.” Nature 352: 624-628 (1991). Jones et al., “Replacing the Complementarity-Determining Regions Cunningham et al., “High-Resolution Epitope Mapping of hCGH in a Human Antibody with Those from a Mouse.” Nature 321:522 Receptor Interactions by Alanine-Scanning Mutagenesis.” Science 525 (1986). 244: 1081-1085 (1989). Kanai et al., “Anti-Tumor and Anti-Metastatic Effects of Human de Wildt et al., “Antibody Arrays for High-Throughput Screening of Vascular-Endothelial-Growth-Factor-Neutralizing Antibody on Antibody-Antigen Interactions.” Nat. Biotechnol. 18: 989-994 Human Colon and Gastric Carcinoma Xenotransplanted Orthotopi (2000). cally Into Nude Mice.” Int. J. Cancer 77: 933-936 (1998). Denget al., “Selection of Antibody Single-Chain Variable Fragments Kim et al., “The Vascular Endothelial Growth Factor Proteins: Iden with Improved Carbohydrate Binding by Phage Display,” J. Biol. tification of Biologically Relevant Regions by Neutralizing Chem. 269.9533-9538 (1994). Monoclonal Antibodies.” Growth Factors 7:53-64 (1992). Deshayes et al., “Rapid Identification of Small Binding Motifs with Kim et al., “Inhibition of Vascular Endothelial Growth Factor-In High-Throughput Phage Display: Discovery of Peptidic Antagonists duced Angiogenesis Suppresses Tumour Growth. In Vivo.” Nature of IGF-1 Function.” Chem. Biol. 9: 495-505 (2002). 362: 841-844 (1993). Dvorak et al., “Vascular Permeability Factor/Vascular Endothelial Klagsbrun et al., “Regulators of Angiogenesis.” Annu. Rev. Physiol. Growth Factor, Microvascular Hyperpermeability, and 53: 217-239 (1991). Angiogenesis.” Am. J. Pathol. 146: 1029-1039 (1995). Klohs et al., “Antiangiogenic Agents.” Curr. Opin. Biotechnol. 10: Ellis et al., “Surgical Resection. After Downsizing of Colorectal Liver 544-549 (1999). Metastasis in the Era of Bevacizumb. J. Clin. Oncol. 23: 4853-4855 Knappik et al., “Fully Synthetic Human Combinatorial Antibody (2005). Libraries (HuCAL) Based on Modular Consensus Frameworks and Ferrara et al., “Molecular and Biological Properties of the Vascular CDRs Randomized with Trinucleotides. J. Mol. Biol. 296: 57-86 Endothelial Growth Factor Family of Proteins.” Endocr: Rev. 13: (2000). 18-32 (1992). Kobrin et al., “A V Region Mutation in a Phosphocholine-Binding Ferrara et al., “Heterozygous Embryonic Lethality Induced by Tar Monoclonal Antibody Results in Loss of Antigen Binding.” J.